Ignite Creation Date:
2025-12-24 @ 11:03 PM
Ignite Modification Date:
2025-12-25 @ 8:34 PM
Study NCT ID:
NCT03580369
Status:
COMPLETED
Last Update Posted:
2023-07-24
First Post:
2018-06-26
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Phase III Study of Safety and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-10-17
Start Date Type:
ACTUAL
Primary Completion Date:
2021-07-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-06-14
Completion Date Type:
ACTUAL
First Submit Date:
2018-06-26
First Submit QC Date:
None
Study First Post Date:
2018-07-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-11-30
Results First Submit QC Date:
None
Results First Post Date:
2022-12-30
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2021-07-02
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2023-07-20
Last Update Post Date:
2023-07-24
Last Update Post Date Type:
ACTUAL